These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 22271681)

  • 1. The enhanced pre- and postnatal study for nonhuman primates: update and perspectives.
    Weinbauer GF; Fuchs A; Niehaus M; Luetjens CM
    Birth Defects Res C Embryo Today; 2011 Dec; 93(4):324-33. PubMed ID: 22271681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The enhanced pre- and postnatal development study for monoclonal antibodies.
    Weinbauer GF; Luft J; Fuchs A
    Methods Mol Biol; 2013; 947():185-200. PubMed ID: 23138905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developmental toxicity testing of monoclonal antibodies: an enhanced pre- and postnatal study design option.
    Stewart J
    Reprod Toxicol; 2009 Sep; 28(2):220-5. PubMed ID: 19379807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Object discrimination reversal as a method to assess cognitive impairment in nonhuman primate enhanced pre- and postnatal developmental (ePPND) studies: statistical power analysis.
    Cappon GD; Bowman CJ; Hurtt ME; Grantham LE
    Birth Defects Res B Dev Reprod Toxicol; 2012 Oct; 95(5):354-62. PubMed ID: 22930561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Group size experiences with enhanced pre- and postnatal development studies in the long-tailed macaque (
    Luetjens CM; Fuchs A; Baker A; Weinbauer GF
    Primate Biol; 2020; 7(1):1-4. PubMed ID: 32232119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Embryo fetal development studies in nonhuman primates.
    Fuchs A; Buse E; Weinbauer GF
    Methods Mol Biol; 2013; 947():169-83. PubMed ID: 23138904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cynomolgus monkey as a model for developmental toxicity studies: variability of pregnancy losses, statistical power estimates, and group size considerations.
    Jarvis P; Srivastav S; Vogelwedde E; Stewart J; Mitchard T; Weinbauer GF
    Birth Defects Res B Dev Reprod Toxicol; 2010 Jun; 89(3):175-87. PubMed ID: 20544806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Considerations regarding nonhuman primate use in safety assessment of biopharmaceuticals.
    Buckley LA; Chapman K; Burns-Naas LA; Todd MD; Martin PL; Lansita JA
    Int J Toxicol; 2011 Oct; 30(5):583-90. PubMed ID: 22013138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development in the cynomolgus macaque following administration of ustekinumab, a human anti-IL-12/23p40 monoclonal antibody, during pregnancy and lactation.
    Martin PL; Sachs C; Imai N; Tsusaki H; Oneda S; Jiao Q; Treacy G
    Birth Defects Res B Dev Reprod Toxicol; 2010 Oct; 89(5):351-63. PubMed ID: 20540088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced normograms and pregnancy outcome analysis in nonhuman primate developmental toxicity studies.
    Grossmann H; Weinbauer GF; Baker A; Fuchs A; Luetjens CM
    Reprod Toxicol; 2020 Aug; 95():29-36. PubMed ID: 32413491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developmental toxicity testing of biopharmaceuticals in nonhuman primates: previous experience and future directions.
    Martin PL; Weinbauer GF
    Int J Toxicol; 2010 Dec; 29(6):552-68. PubMed ID: 20926830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developmental immunotoxicology assessment of rituximab in cynomolgus monkeys.
    Vaidyanathan A; McKeever K; Anand B; Eppler S; Weinbauer GF; Beyer JC
    Toxicol Sci; 2011 Jan; 119(1):116-25. PubMed ID: 20937725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developmental and reproductive toxicology studies in nonhuman primates.
    Chellman GJ; Bussiere JL; Makori N; Martin PL; Ooshima Y; Weinbauer GF
    Birth Defects Res B Dev Reprod Toxicol; 2009 Dec; 86(6):446-62. PubMed ID: 20025046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternatives to Monkey Reproductive Toxicology Testing for Biotherapeutics.
    Hoberman AM; Maki K; Mikashima F; Naota M; Wange RL; Lansita JA; Weis SL
    Int J Toxicol; 2023 Dec; 42(6):467-479. PubMed ID: 37714565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The developmental toxicity testing of biologics.
    Hazelden KP
    Methods Mol Biol; 2013; 947():31-6. PubMed ID: 23138893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A critical evaluation of developmental and reproductive toxicology in nonhuman primates.
    Faqi AS
    Syst Biol Reprod Med; 2012 Feb; 58(1):23-32. PubMed ID: 22239078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotoxicity testing in nonhuman primates.
    Grote-Wessels S; Frings W; Smith CA; Weinbauer GF
    Methods Mol Biol; 2010; 598():341-59. PubMed ID: 19967524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety assessment of biopharmaceuticals: Japanese perspective on ICH S6 guideline maintenance.
    Nakazawa T; Kurokawa M; Kimura K; Wakata A; Hisada S; Inoue T; Sagami F; Heidel SM; Kawakami K; Shinoda K; Onodera H; Kumagai Y; Ohno Y; Kawamura N; Yamazaki T; Inoue T
    J Toxicol Sci; 2008 Aug; 33(3):277-82. PubMed ID: 18670158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety evaluation of biological drugs: what are toxicology studies in primates telling us?
    Baldrick P
    Regul Toxicol Pharmacol; 2011 Mar; 59(2):227-36. PubMed ID: 20937341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of embryo-fetal developmental toxicity studies performed for recent FDA-approved pharmaceuticals.
    Ishihara-Hattori K; Barrow P
    Reprod Toxicol; 2016 Sep; 64():98-104. PubMed ID: 27112525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.